Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.96

+3.0%

Nov 24 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: arnold silver who wrote (503)	1/30/2004 3:24:00 PM
From: Jibacoa	Read Replies (2) of 3722

Hi Arnie: HEB Is doing well. It is up more than 15% today on a volume of 500K which is more than 3x its daily average. (up for a third day on a roll.<g>) It made a 52 wks.H and it is now trading above its March 2002 Hs Its next resistance seems now to be its January 2002 H at 4.95 and then the December 2001 H at 5.29 bigcharts.marketwatch.com It is responding to the announcement this week of the results of a study conducted by Professor Johan Neyts of the Rega Institute in Belgium that suggests that HEB's Ampligen is effective in treating Coxsackie virus infections, which are responsible for many cases of acute myocarditis. According to the study,treatment with Ampligen decreased the foci of myocarditis by 98% and showed 10x better results than recombinant interferon and 15x better than pegelated interferon which are the present standard of care in several human viral infections.. HEB also announced this week a new clinical program for the treatment of West Nile Virus in collaboration with New York Hospital.(The CDC reported close to 9K cases of WNV with more than 200 deaths in 2003 and the present standard of treatment is only supportive care.) HEB reportedly has $5M in cash (about $0.13/share)and $1.3M of LTD with a CR of 3.9 and BookV of $0.19 There are more than 37M shares out with the insiders holding close to 9M and the float around 34M There were some reported insiders buys in November.In September they signed a pact with Guandong Medical Group to organize medical trials.HEB's drugs are being developed for other important viral diseases including HPV,SARS, HIV, CFS and Hepatitis. Revenues have remained essentially unchanged around $800K and it seems the loss in the current year will be also around $0.21/share. It seems the shares may get to test the $6 level in a not too distant future.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next